Results 101 to 110 of about 34,778 (264)

L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications

Epilepsia, EarlyView.
Abstract Objective Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power.
Wesley T. Kerr, Neo Kok, Katherine N. McFarlane, Advith S. Reddy, Lavanya Biju, Jacqueline A. French, Daniel M. Goldenholz   +6 more
wiley   +1 more source

Continuous outcome estimation in N‐of‐1 trials for accelerated decision‐making

Epilepsia, EarlyView.
Abstract Objective N‐of‐1 trials aim to determine the therapeutic effect for a single individual. This individualized approach necessitates collecting multiple data points over time through repeated alternating periods of active treatment and a comparator or control condition.
Victoria Defelippe, František Bartoš, Eric‐Jan Wagenmakers, Kees P. J. Braun, Floor E. Jansen, Willem M. Otte   +5 more
wiley   +1 more source

Has integrated medical insurance scheme enhanced happiness of returning migrant workers? Evidence from China

Frontiers in Public Health
Using four waves of panel data from the China Labor-force Dynamic Survey (CLDS) spanning from 2012 to 2018, regarding gradual reforms of the Integrated Medical Insurance Scheme (IMIS) in China as a quasi-experiment, we establish a time-varying difference-
Yupeng Shen, Yiming Meng, Yiyue Shan, Shichen Zhang, Daorui Tang, Zhengxiu Sun, Zhengxiu Sun   +6 more
doaj   +1 more source

Video‐based diagnostics supported by artificial intelligence as an opportunity to address the epilepsy diagnostic gap: A narrative review

Epilepsia, EarlyView.
Abstract Despite advancements in epilepsy care, a substantial diagnostic gap persists, particularly in resource‐limited settings. This narrative review explores the potential of video‐based diagnostics augmented by artificial intelligence (AI) to address this gap by enabling earlier and more accessible seizure detection and classification.
Gadi Miron, Robert Terziev, Maximilian Schöls, John McLaren, Tobias Loddenkemper, Jörg Wellmer, Sigrid Mues, Christian Meisel   +7 more
wiley   +1 more source

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs

Epilepsia, EarlyView.
Abstract Objective The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced ...
Stéphane Auvin, Alexis Arzimanoglou, Jacqueline French, Kelly G. Knupp, Lieven Lagae, Eugen Trinka, Dennis Dlugos, Emilio Perucca   +7 more
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Sudden unexpected death in epilepsy (SUDEP): Risk management of pediatric patients with epilepsy

Epilepsia Open, EarlyView.
Abstract Objective Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in people with epilepsy with an incidence of 1:1000. The primary risk factors for SUDEP are generalized or focal to bilateral tonic–clonic seizures. Preventive measures like nighttime monitoring devices and resuscitation training address modifiable risk factors.
Laura Lutz, Lena Luise Becker, Alwina Koch, Angela M. Kaindl   +3 more
wiley   +1 more source

When Rare Is Not Small: Amyotrophic Lateral Sclerosis Initiatives and Therapy

Exploration, EarlyView.
In the precision‐medicine era, rare diseases must not be sidelined in translational infrastructure. The Mr. Cai Lei—led “Ice‐Breaking Team” turns an amyotrophic lateral sclerosis patient community into a sustainable ecosystem, realigning philanthropy, data, and research and development to reshape rare‐disease pipelines and guide precision therapies ...
Yang Liu, Xue Xia, Yingfang Chen, Haoying Yang, Xiaochen Chen, Lei Cai, Bingyang Shi   +6 more
wiley   +1 more source

Characteristics, Motivators, and Enablers of Educators Who Earn Many Micro‐Credentials

Future in Educational Research, EarlyView.
ABSTRACT This study explores the characteristics, motivators, and enablers of US educators, who earned more than ten micro‐credentials. Although research exists on attitudes and motivators associated with educators newly engaging with micro‐credentials, it lacks insights into learners earning many micro‐credentials.
Marilys Galindo, Rita Fennelly‐Atkinson   +1 more
wiley   +1 more source

Paying for Health Gains Using Patient Reported Outcome Measures

Health Economics, EarlyView.
ABSTRACT Payments to healthcare providers are often based on the number of patients with a particular diagnosis or treatment with well known limitations. Payment based on health outcomes, a form of pay‐for‐performance, has long been advocated as a possible solution.
Luigi Siciliani, James Gaughan, Nils Gutacker, Hugh Gravelle, Martin Chalkley   +4 more
wiley   +1 more source